Renewed interest in TCF related assets27 May 2025 10:58
Studies have shown that Ox-1 plays an important role
across a range of neuropsychiatric conditions such as anxiety, impulse and substance use disorders,
significant markets which remain underserved by existing treatment options. Additionally, there is a
renewed positive market sentiment in neuroscience drug development, evidenced by a number of
notable M&A transactions over the past 12-18 months, including most recently J&J’s (January 2025)
$14.6bn acquisition of CNS specialist, Intra-Cellular Therapies.
— Newsflow: With the extended cash runway following the £4.25m equity fundraise completed in March